Sat, Jan 31, 2015, 6:25 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Curis, Inc. Message Board

  • derekrepath May 15, 2013 10:27 PM Flag


    The report seems good but need someone with knowledge so could Bigl please comment on it

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • CUDC 427 (the recently in-licensed GDC-0917) has some P1 data that looks resonable, 5% uCRs in a mix of patients. As usuall though it really is hard to glean more than "looks OK to keep going" on these trials.

      For vismo, the STEVIE trial interum data looks to be tracking previous data, so no real news (though, no news is good news to some extent). The long term follow up on EVIRANCE does show some good news with response durration lengthening (the expected/hopefull result).

    • the chatter for iap cudc 427 is that it looked safe and it as a single agent had some complete responses and stable disease. remember that iap really shows its potential when combined with chemo which will be phase 2. they have indicated that they might investigate the iap as single agent for possible mutation if they find it. dont forget the investor conferences at the end of the month too. we should get more updates on cudc 907 on cohort 1 and 2. that to me is even bigger than asco data....

1.84-0.020(-1.08%)Jan 30 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.